Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases

摘要

The present invention provides for the identification of individuals having neurodegenerative diseases (ND). Peptoids recognized by Parkinson's Disease- and Alzheimer's Disease-specific antibodies are identified, allowing one to diagnose or predict ND in subjects.

主权项

1. A method of detecting antibodies in an antibody-containing sample from a patient suspected of or having a neurodegenerative disease comprising:
(a) contacting an antibody-containing sample with a support having affixed thereto a peptoid having a formula selected from:
(i) the formula (1A): wherein,R1 is independently selected from C1-6alkyl or C2-6alkenyl or C1-6alkyl substituted with —OH or NH2 or —COOH; or piperonyl or C1-3alkylphenyl;R2 is C1-3alkylphenyl;R3 is C1-3alkylphenyl;R4 is independently selected from C1-6alkyl or C2-6alkenyl or C1-6alkyl substituted with —OH or NH2 or —COOH; or piperonyl or C1-3alkylphenyl;R5 is C1-4alkyl substituted with —OH or NH2; or(ii) formula (1B): whereinR6 is independently selected from C2-6alkenyl, C1-6alkyl independently and optionally substituted with —OH, NH2 or —COOH; piperonyl or C1-6alkylphenyl;R7 is independently selected from C2-6alkenyl, C1-6alkyl independently and optionally substituted with —OH, NH2 or —COOH; piperonyl;R8 is independently selected from C2-6alkenyl, C1-6alkyl independently and optionally substituted with —OH, NH2 or —COOH; piperonyl; or(iii) formula (1C): whereinR9, R11 and R13 are independently selected from C2-6alkenyl, C1-6alkyl independently and optionally substituted with —OH, NH2 or —COOH; piperonyl or C1-6alkylphenyl;R10 is piperonyl;R12 is C1-6alkyl substituted with —OH, NH2 or —COOH;R14 is C1-6alkyl substituted with —OH, NH2 or —COOH; or(iv) formula (1D): wherein,R17 is independently selected from the group consisting of C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R18 is selected from C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R19 is selected from C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R20 is selected from C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R21 is selected from C1-6alkylphenyl;R22 is selected from C1-6alkylphenyl;R23 is selected from C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R24 is selected from C1-6alkyl substituted with —OH, NH2 or —COOH;n is 1; orfor a compound of formula 1D,R17 is C2-6alkenyl;R18 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R19 is piperonyl;R20 is C2-6alkenyl;R21 is C2-6alkenyl;R22 is C2-6alkenyl;R23 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R24 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;n is 1; or for a compound of formula 1D,R17 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R18 is piperonyl;R19 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R20 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R21 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R22 is C1-6alkylphenyl;R23 is C1-6alkyl optionally substituted with —OH, NH2 or —COOH;R24 is C1-6alkyl substituted with —OH, NH2 or —COOH;n is 1; wherein L is an optional linker moiety, M is a substrate or support; and m, n, o, and/or p, unless specified, is 0-6, and wherein Z is a functional group capable of coupling to a linker, substrate, or a label; and (b) detecting antibodies bound to said peptoid, wherein antibodies bound to said peptoid are indicative of a neurodegenerative disease in said subject.